Since ESR2 and NDRG2 are markedly low in colorectal cancer, enhancing ESR2 by blocking UBE3A-mediated degradation of ESR2 could offer a therapeutic target for CRC (Zhu et al., 2020). This evidence concerns the gene ESR2 and colorectal carcinoma.